Evidence map›Paper›PMID 29971593›Full record

Trial reportIntensive care medicine2018

Terlipressin versus norepinephrine as infusion in patients with septic shock: a multicentre, randomised, double-blinded trial.

Zi-Meng Liu, Juan Chen, Qiuye Kou, Qinhan Lin, Xiaobo Huang, Zhanhong Tang, Yan Kang, Ke Li, Lixin Zhou, Qing Song and 16 more

Registry-linked trialAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Intensive care medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01697410 (A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock), which is not on this map. Cited by 63 papers, 14 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 14 pooled it
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01697410 naunknown statusnot on this map

A Multicenter,Prospective,Randomized,Controlled,Double Blind Study in China to Evaluate the Effect of Terlipressin in Patients With Septic Shock

TypeinterventionalSponsorFirst Affiliated Hospital, Sun Yat-Sen UniversityRan2013 to 2016Enrolled1,000ConditionsSeptic ShockArmsTerlipressin, Norepinephrine
3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 14 syntheses or guidelines pooled it, 128 citations in OpenAlex.

  1. [S3 guideline on sepsis-prevention, diagnosis, therapy, and follow-up care-update 2025].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2025
    Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Norepinephrine in Septic Shock: A Systematic Review and Meta-analysis.The western journal of emergency medicine · 2021
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Trial
  16. Trial
  17. Trial
  18. The poikilothermic hypothesis of sepsis.Critical care (London, England) · 2026
    Review
  19. Article
  20. Review

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 18 institutions in 1 country.

Zi-Meng LiuDepartment of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Juan ChenDepartment of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Qiuye KouDepartment of Critical Care Medicine, The Sixth Affiliated Hospital of Sun Yat-sen University, 26 Yuancun Erheng Road, Guangzhou, 510080, China.
Qinhan LinDepartment of Critical Care Medicine, Qingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, 24 Yinquan Road, Qingyuan, 511500, Guangdong, China.
Xiaobo HuangDepartment of Critical Care Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, 32 West Second Section First Ring Road, Chengdu, Sichuan, 610000, China.
Zhanhong TangDepartment of Critical Care Medicine, The First Affiliated Hospital, GuangXi Medical University, 6 Shuangyong Road, Nanning, 530021, Guangxi, China.
Yan KangDepartment of Critical Care Medicine, West China Hospital, Sichuan University, 37 Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Ke LiDepartment of Critical Care Medicine, Chinese PLA 302 Hospital, 100 Xisihuan Middle Road, Beijing, 100000, China.
Lixin ZhouDepartment of Critical Care Medicine, Foshan First Municipal People's Hospital, 81 Lingnan North Road, Foshan, 528000, Guangdong, China.
Qing SongDepartment of Critical Care Medicine, Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100000, China.
Tongwen SunDepartment of Critical Care Medicine, The First Affiliated Hospital, Zhengzhou University, 1 Jianshe East Road, Zhengzhou, 450000, Henan, China.
Ling ZhaoDepartment of Critical Care Medicine, Zhuhai People's Hospital, 79 Kangning Road, Zhuhai, 519000, Guangdong, China.
Xue WangDepartment of Critical Care Medicine, The First Affiliated Hospital, Xi An JiaoTong University, 277 Yanta West Road, Xi an, 710000, Shanxi, China.
Xiandi HeDepartment of Critical Care Medicine, The First Affiliated Hospital, Bengbu Medical College, 287 Changhuai Road, Bengbu, 233000, Henan, China.
Chunting WangDepartment of Critical Care Medicine, Shandong Provincial Hospital, 324 Jingwuweiqi Road, Jinan, 250000, Shandong, China.
Benquan WuDepartment of Critical Care Medicine, The Third Affiliated Hospital of Sun Yat-sen University, 600 TianHe Road, Guangzhou, 510080, China.
Jiandong LinDepartment of Critical Care Medicine, Fujian Provincial Hospital, 134 East Street Fuzhou, Fujian, 350000, China.
Shiying YuanDepartment of Critical Care Medicine, Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 127 Jiefangda Road Wuhan, Hubei, 430000, China.
Qin GuDepartment of Critical Care Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School, 321 Zhongshan Road, Nanjing, 210000, Jiangsu Province, China.
Kejian QianDepartment of Critical Care Medicine, The First Affiliated Hospital, Nanchang University, 17 Yongwaizheng Road, Nanchang, 330006, Jiangxi, China.
Xianqing ShiDepartment of Critical Care Medicine, Guizhou Provincial Hospital, 97 Boai Road, Guiyang, 550002, Guizhou, China.
Yongwen FengDepartment of Critical Care Medicine, The Second People's Hospital of Shenzhen, Sungang Road, Shenzhen, 518000, Guangdong, China.
Aihua LinSchool of Public Health, Sun Yat-sen University, 74 Zhongshan 2nd Road, Guangzhou, 510080, China.
Xiaoshun HeDepartment of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, China.
Study Group of investigators
Xiang-Dong GuanDepartment of Critical Care Medicine, The First Affiliated Hospital, Sun Yat-sen University, 58 Zhongshan 2nd Road, Guangzhou, 510080, China. guanxiangdong1962@163.com.
Sun Yat-sen University · CN302 Military Hospital of China · CNChinese PLA General Hospital · CNFirst Affiliated Hospital of GuangXi Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNFirst Affiliated Hospital of Zhengzhou University · CNFirst People's Hospital of Foshan · CNFujian Provincial Hospital · CNGuangzhou Medical University · CNGuizhou Provincial People's Hospital · CNNanchang University · CNNanjing Drum Tower Hospital · CNShandong Provincial Hospital · CNShenzhen Second People's Hospital · CNSichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital · CNSichuan University · CNWuhan Union Hospital · CNZhuhai People's Hospital · CN

Funding

Major Science and Technology Project of GuangDong province 2012A080204018Sun Yat-sen University Clinical Research Program 5010 2007015
6 · The paper itself

Abstract

purposeRecent clinical data suggest that terlipressin, a vasopressin analogue, may be more beneficial in septic shock patients than catecholamines. However, terlipressin's effect on mortality is unknown. We set out to ascertain the efficacy and safety of continuous terlipressin infusion compared with norepinephrine (NE) in patients with septic shock.

methodsIn this multicentre, randomised, double-blinded trial, patients with septic shock recruited from 21 intensive care units in 11 provinces of China were randomised (1:1) to receive either terlipressin (20-160 µg/h with maximum infusion rate of 4 mg/day) or NE (4-30 µg/min) before open-label vasopressors. The primary endpoint was mortality 28 days after the start of infusion. Primary efficacy endpoint analysis and safety analysis were performed on the data from a modified intention-to-treat population.

resultsBetween 1 January 2013 and 28 February 2016, 617 patients were randomised (312 to the terlipressin group, 305 to the NE group). The modified intention-to-treat population comprised 526 (85.3%) patients (260 in the terlipressin group and 266 in the NE group). There was no significant difference in 28-day mortality rate between the terlipressin group (40%) and the NE group (38%) (odds ratio 0.93 [95% CI 0.55-1.56]; p = 0.80). Change in SOFA score on day 7 was similar between the two groups: - 7 (IQR - 11 to 3) in the terlipressin group and - 6 (IQR - 10 to 5) in the NE group. There was no difference between the groups in the number of days alive and free of vasopressors. Overall, serious adverse events were more common in the terlipressin group than in the NE group (30% vs 12%; p < 0.001).

conclusionsIn this multicentre, randomised, double-blinded trial, we observed no difference in mortality between terlipressin and NE infusion in patients with septic shock. Patients in the terlipressin group had a higher number of serious adverse events.

trial registrationThis trial is registered at ClinicalTrials.gov: ID NCT01697410.

Indexed as

Critical CareAdultAgedChinaDouble-Blind MethodFemaleHumansInfusions, IntravenousMaleMiddle AgedNorepinephrineShock, SepticSurvival RateTerlipressinTreatment OutcomeVasoconstrictor AgentsNorepinephrineTerlipressinVasoconstrictor AgentsNorepinephrineSeptic shockSOFA scoreTerlipressin

Identifiers

PMID29971593
OpenAlexW2810109598

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.